Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 12/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16347077 | 1.00 | EZH2 (0.55) | EZH2BRD4BAZ2APOLB | |
| SCHEMBL22401126 | 1.00 | EZH2 (0.55) | EZH2BRD4BAZ2APOLB | |
| SCHEMBL16347078 | 1.00 | EZH2 (0.55) | EZH2BRD4BAZ2APOLB | |
| SCHEMBL16344488 | 0.88 | EZH2 (0.54) | EZH2 | |
| SCHEMBL23682342 | 0.87 | EZH2 (0.55) | EZH2 | |
| SCHEMBL16403353 | 0.87 | EZH2 (0.55) | EZH2 | |
| SCHEMBL16376978 | 0.87 | EZH2 (0.55) | EZH2 | |
| SCHEMBL29966225 | 0.87 | EZH2 (0.55) | EZH2 | |
| SCHEMBL22401114 | 0.86 | EZH2 (0.55) | EZH2 | |
| SCHEMBL22401116 | 0.86 | EZH2 (0.55) | EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459315-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3707136-B1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20210230148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20200361914-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200361914-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-11-19 | — | — | US | disclosed |
| EP-3707136-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-RE47428-E1 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190125737-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2019-05-02 | — | — | US | disclosed |
| US-10016405-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016405-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20150368229-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150368229-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150259351-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150259351-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-20150209345-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-07-30 | — | — | US | disclosed |
| US-9085583-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | Constellation—Pharmaceuticals, Inc. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085583-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | Constellation—Pharmaceuticals, Inc. (US) | 2015-07-21 | — | — | US | disclosed |
| WO-2015010078-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2015-01-22 | — | — | WO | disclosed |
| US-20150011546-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | disclosed |
| US-20150011546-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209345-A1 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | ALDH1A2, CLN6, PLA2G2E | EZH2 4642/4885BRD4 4551/4885BAZ2A 3885/4885 |
| US-11459315-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | TPMT, TET1, TET2 | EZH2 150/4885BRD4 1778/4885BAZ2A 1838/4885 |
| US-10016405-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | TET1, TET3, EHMT2 | EZH2 61/4885BRD4 415/4885BAZ2A 205/4885 |
| US-20150011546-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | EZH2 61/4885BRD4 415/4885BAZ2A 205/4885 |
| US-20190125737-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | EZH2 61/4885BRD4 415/4885BAZ2A 205/4885 |
| US-20150368229-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | EZH2 61/4885BRD4 415/4885BAZ2A 205/4885 |
| US-20200361914-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | BCOR, CYP2B6, AHR | EZH2 1546/4885BRD4 9/4885BAZ2A 382/4885 |
| US-20150259351-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | EZH2 61/4885BRD4 415/4885BAZ2A 205/4885 |
| US-20210230148-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TPMT, TET1, TET2 | EZH2 150/4885BRD4 1778/4885BAZ2A 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.